宜明昂科生物医药技术（上海）股份有限公司（股票代码：01541，股票简称：宜明昂科-B）于2026年7月3日发布翌日报表，披露当日于香港联交所场内回购2.54万股H股，占回购前已发行股本（不含库存股）约0.0061%。本次回购价格介乎每股港币3.80元至3.93元，总计约港币9.82万元。
回购完成后，公司于2026年7月3日的已发行股本（不含库存股）为419,010,105股，库存股数增至1,467,200股，公司总股份数维持在420,477,305股。公司此前于2026年5月28日通过购回授权，可回购股份总数为43,150,769股，截至目前已回购1,467,200股，约占授权通过当日已发行股本（不含库存股）的0.34%。本次回购后，自2026年7月3日至2026年8月3日期间，公司将暂缓进行任何新股发行或出售、转让库存股事宜，遵守相关规则要求。
公司确认，本次股份回购已经董事会正式授权，符合香港联交所证券上市规则及相关法律法规的规定。公告由执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.